<DOC>
	<DOCNO>NCT00516282</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide VNP40101M , work different way stop growth tumor cell , either kill cell stop dividing . Temozolomide may also stop growth tumor cell block blood flow tumor . PURPOSE : This phase I/II trial study side effect best dose VNP40101M give together temozolomide see well work treat patient progressive relapse malignant glioma .</brief_summary>
	<brief_title>VNP40101M Temozolomide Treating Patients With Progressive Relapsed Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose ( MTD ) VNP40101M administer temozolomide patient progressive relapse ( first relapse ) malignant glioma . ( Phase I ) - To record toxicity VNP40101M administer temozolomide . ( Phase I II ) - To measure level AGT expression peripheral blood monocyte treatment temozolomide prior administration VNP40101M . ( Phase I II ) - To determine MGMT methylation status well methylation pattern blood tissue patient treat regimen correlate outcome . ( Phase I II ) - To determine 6- 12-month progression-free survival rate patient treated regimen . ( Phase II ) - To determine overall survival patient treat regimen . ( Phase II ) - To determine complete partial response rate patient treated regimen . ( Phase II ) - To determine CSF penetration VNP40101M MTD reach phase I correlate serum/plasma pharmacokinetics . ( Phase II ) OUTLINE : - Phase I : Patients receive oral temozolomide day 1-7 VNP40101M IV 15-30 minute 2 hour last dose temozolomide day 7 . Treatment repeat every 7 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos VNP40101M maximum tolerate dose ( MTD ) determine The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . - Phase II : Patients receive oral temozolomide VNP40101M phase I. VNP40101M give MTD determine phase I . In phase , patient complete Functional Assessment Cancer Therapy-Brain ( FACT-BR ) questionnaire day 1 course . Blood collect vitro isolation mononuclear cell analysis O^6 alkylguanine DNA alkyltransferase day 1 7 course 1 . Blood , plasma , CSF , formalin-fixed paraffin-embedded tissue block collect gene methylation study , include MGMT , baseline day 1 course .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically prove malignant glioma include follow : Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix oligoastrocytoma Malignant astrocytoma otherwise specified Unequivocal evidence tumor recurrence progression MRI CT scan contrast No one relapse Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : More 2 week surgery recover effect surgery Evaluable measurable disease follow resection recurrent tumor mandate eligibility study treatment failure evaluate Enhanced CT scan/ MRI do later 96 hour immediate postoperative period 46 week postoperatively If 96hour scan 2 week registration , scan need repeat A baseline scan perform within 14 day prior registration steroid dosage stable 5 day otherwise new baseline MRI/CT require The type scan ( i.e. , MRI CT scan ) must use throughout period protocol treatment tumor measurement Must fail prior externalbeam radiotherapy Must fail one prior systemic treatment chemotherapy biologic agent PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 60100 % Life expectancy &gt; 12 week WBC &gt; 3,000/mm³ ANC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 10 mg/dL AST ALT &lt; 4 time upper limit normal ( ULN ) Bilirubin &lt; 2 time ULN Creatinine &lt; 1.5 time ULN Fertile patient must use acceptable contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) Negative pregnancy test Not pregnant nursing Exclusion criterion : Active uncontrolled bleed Active infection kind Unwilling unable follow protocol requirement give informed consent Active heart disease include follow : Myocardial infarction within past 3 month Uncontrolled arrhythmias Uncontrolled coronary artery disease Uncontrolled congestive heart failure Known HIVpositive patient ( HIV test require ) History cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) unless complete remission therapy disease minimum 3 year PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Recovered prior therapy At least 2 week since prior vincristine More 4 week since prior cytotoxic therapy ( 6 week nitrosoureas ) More 4 week since prior radiotherapy More 4 week since prior experimental biologic agent ( e.g. , EGFR inhibitor , etc ) More 3 week since prior procarbazine administration More 2 week since prior noncytotoxic agent ( e.g. , interferon , tamoxifen , thalidomide , isotretinoin ) Radiosensitizer count At least 2 week since prior concurrent enzyme induce anticonvulsant If patient enzyme induce anticonvulsant , may convert nonenzyme induce anticonvulsant Exclusion criterion : Any concurrent standard investigational treatment cancer , investigational agent indication Concurrent disulfiram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>